• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Abdominal Neoplasms

Abdominal Neoplasms - 350 Studies Found

Terminated : Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Can
    : 2008-04-03
    :
    • Drug: atrasentan hydrochloride

Terminated : Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Can
    : 2008-04-03
    :
    • Biological: Allopurinol All pa

Active, not recruiting : Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Peritoneal Cavity Cancer

: 2008-04-03
:
  • Biological: filgrastim
  • Drug: carboplatin

Terminated : A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
:
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer : 2008-03-10
    : Drug: Alemtuzumab will be given Alemtuzumab therapy three times in your first week on the study and then
Completed : Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
: Ovarian Cancer, Primary Peritoneal Cancer
: 2008-03-05
:
  • Drug: M200 (Volociximab) 7.5 m

Withdrawn : Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer : 2008-03-06
    :
    • Drug: Femara 2.5 mg by mouth d

Completed : A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission
:
  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Pe
    : 2008-02-04
    :
    • Biological: NY-ESO-1 OLP4 1 mg

Withdrawn : DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer
:
  • Ovarian Cancer
  • Primary Peritoneal Cancer

: 2008-01-16
: Biological: DCVax-L and T Cells Arm A
Withdrawn : Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
:
  • Breast Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • : 2008-01-25
    :
    • Genetic: gene expression analysis
    • Genetic:

Completed : AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
:
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Ca
    : 2007-12-14
    : Drug: motesanib diphosphate
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.